MetaCap

Amarin (AMRN) vs Lyell Immunopharma (LYEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lyell Immunopharma (LYEL) has outperformed Amarin (AMRN) over the past year, losing 27.9% versus a loss of 35.5%. Over five years, AMRN leads with a -85.5% price change compared with -92.6% for LYEL. Amarin is the larger company by market cap ($444.4 million vs $441.8 million), about 1.0 times the size.

Amarin converts more of its revenue into profit, with a net margin of -18.2% versus -762355.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRN-35.47%LYEL-27.86%
+110%+21%-69%
Nov 21, 20251 yearNov 20, 2026
AMRN-86.45%LYEL-93.62%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRN versus LYEL key metrics
MetricAMRNLYEL
Share price$10.57$13.80
Market cap$444.39M$441.82M
1-day change-6.13%+1.62%
YTD return-24.28%-55.17%
1-year return-35.47%-27.86%
5-year return-85.48%-92.59%
Forward P/E10.79—
EPS (TTM)$-0.80$-12.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$213.65M$36.00K
Revenue growth (YoY)-6.55%-40.98%
Net income (latest FY)$-38.80M$-274.45M
Gross margin56.57%—
Operating margin-23.48%-748344.44%
Net margin-18.16%-762355.56%
52-week high$17.31$45.00
52-week low$10.56$7.20
Distance from 52-week high-38.94%-69.33%
Analyst consensusnonebuy
Avg. price target upside+22.99%+172.68%
Average volume79.50K174.76K
Shares outstanding42.04M32.02M
Employees80161
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Amarin is more profitable, keeping -18.2 cents of every revenue dollar as net income versus -762355.6 cents for Lyell Immunopharma.
  • Amarin grew revenue faster in its latest fiscal year (-6.55% vs -40.98%).

About Amarin

AMRN stock →

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About Lyell Immunopharma

LYEL stock →

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

AMRN vs LYEL FAQ

Which is bigger, Amarin or Lyell Immunopharma?

Amarin (AMRN) is larger, with a market capitalization of $444.39M compared with $441.82M for Lyell Immunopharma (LYEL).

Which stock has performed better over the past year, AMRN or LYEL?

LYEL returned -27.86% over the past 12 months, compared with -35.47% for AMRN (price return, excluding dividends). Past performance does not predict future results.

Are Amarin and Lyell Immunopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons